Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Novartis
UBS
Teva
US Army
Fuji
Johnson and Johnson
Harvard Business School
Covington
Medtronic

Generated: January 22, 2018

DrugPatentWatch Database Preview

BIOGEN IDEC Company Profile

« Back to Dashboard

Summary for BIOGEN IDEC
International Patents:604
US Patents:15
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for BIOGEN IDEC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BIOGEN IDEC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-releaseCapsules 120 mg and 240 mg ➤ Subscribe 3/27/2017

Non-Orange Book US Patents for BIOGEN IDEC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,586,559 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences ➤ Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines ➤ Subscribe
7,148,204 Antisense modulation of bcl-x expression ➤ Subscribe
9,476,042 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences ➤ Subscribe
6,172,216 Antisense modulation of BCL-X expression ➤ Subscribe
7,915,310 Utilization of dialkylfumarates ➤ Subscribe
9,107,933 Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III ➤ Subscribe
6,214,986 Antisense modulation of bcl-x expression ➤ Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines ➤ Subscribe
8,946,183 Compositions and methods for modulation of SMN2 splicing ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for BIOGEN IDEC Drugs

Supplementary Protection Certificates for BIOGEN IDEC Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00054 Denmark ➤ Subscribe PRODUCT NAME: NUSINERSEN ELLER SALTE DERAF; REG. NO/DATE: EU/1/17/1188 20170601
2014 00055 Denmark ➤ Subscribe PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630
90039-3 Sweden ➤ Subscribe PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130
90038-5 Sweden ➤ Subscribe PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140203
2014023 Lithuania ➤ Subscribe PRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
00675 Netherlands ➤ Subscribe PRODUCT NAME: DIMETHYLFUMARAAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
2017037 Lithuania ➤ Subscribe PRODUCT NAME: NUSINERSENAS ARBA JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1188/001 20170530
C/GB02/030 United Kingdom ➤ Subscribe PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
2014000069 Germany ➤ Subscribe PRODUCT NAME: DIMETHYLFUMARAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
2014024 Lithuania ➤ Subscribe PRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Chinese Patent Office
Baxter
Moodys
US Army
Colorcon
Cerilliant
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot